Malignancy in scleroderma patients from south west England: a population-based cohort study

Siau, Keith; Laversuch, Catherine; Creamer, Paul; O'Rourke, K

doi:10.1007/s00296-009-1348-y

Cited by 36 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypotheses have been proposed, which suggest that systemic sclerosis and malignancy manifest as a result of alterations in the immune response or genetic background. In a study by Siau et al (3), the average time between initial diagnosis of systemic sclerosis and malignancy was observed to be seven years (3). …”

Section: Discussionmentioning

confidence: 99%

Complications in the treatment of oropharyngeal carcinoma in patients with systemic sclerosis: A case report

et al. 2014

View full text Add to dashboard Cite

Systemic sclerosis is a chronic, progressive disease with an extremely poor prognosis. The incidence of malignant tumors in patients with systemic sclerosis is increased when compared with that of the general population. In certain malignancies, systemic sclerosis presents as a paraneoplastic process. The symptoms of sclerosis in the organs of the head and neck often overlap with symptoms of malignant diseases, which may increase the difficulty of a differential diagnosis. Additionally, the presence of sclerosis may complicate standard examination procedures, due to poor access to the oral cavity and oropharynx. When considering treatment options, it is important to evaluate the surgical and oncological risks to soft tissues of the head and neck with regard to both diseases, as well as the relatively poor prognosis for systemic sclerosis and oropharyngeal cancer. The low incidence of patients with systemic sclerosis and oropharyngeal carcinoma together presents a clear case for a casuistic approach. Based upon our own experience, we can attest to the difficulty of treating such patients. However, we have no evidence to indicate that these patients have reduced tolerance to surgical treatments. The current study presents the case of a 47-year-old female with systemic sclerosis, who was diagnosed with oropharyngeal carcinoma. The patient initially tolerated radiotherapy treatment well, however post-radiotherapy complications occurred. Despite many enigmatic indications to the contrary, it appears that the complications in this instance may be due to late toxicity from radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Complications in the treatment of oropharyngeal carcinoma in patients with systemic sclerosis: A case report

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Large cohort in South West England has found that the prevalence of malignancy is increased in SSc [7]. Up to date it is found out that the concomitant malignancies with SSc are solid organ cancers like lung, breast, stomach, oesophagus, colon, pancreas, larynx, over, thyroid, liver, prostate and blood oriented malignancies including leukaemia, lymphoma, melanomas and non-melanomas.…”

Section: Discussionmentioning

confidence: 99%

“…This concurrence is not resulted from SSc but it is thought to be related with pulmonary Wbrosis. Despite the arguments that cytotoxic treatment may increase possibly the hematologic malignancy risk, a medical study based on oral Cyc proved the contrary [7]. After the discovery of the structure of endogenic PGI2 in 1976 by Vane et al, iloprost has been generated in 1978.…”

Section: Discussionmentioning

confidence: 99%

Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study

et al. 2011

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic disease of unknown etiology which affects the vascular system and connective tissue. A wide series of studies showed an increased prevalence of cancer in patients with SSc than the normal population. Prostacyclin (PGI2) is an endogenously produced element that is basically synthesized by arachiodonic acid through prostacyclin synthesis in vascular system endothelial cells. Iloprost is a stable analogue of PGI2 which is used in the treatment of pulmonary arterial hypertension (PAH). In a limited number of animal models, the anti-metastatic activity of PGI2 is observed. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed PAH as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. These two mortal complications were both treated successfully with inhaled iloprost until her death due to gastrointestinal complications of SSc.

show abstract

“…In some cases, systemic sclerosis could even represent a paraneoplastic syndrome (Vettori et al, 2010). In a population-based cohort study from south-west England to determine if patients with scleroderma have an increased risk of malignancy compared with general population, the highest risk among patients affected by scleroderma was found for haematological malignancies, especially for NHL (RR=25.8) (Siau et al, 2010). Another retrospective analysis of 218 Hungarian patients with SSc followed during a period of 12 years showed lymphoma development in three of them (1.38%), all of B cell phenotype, within 2 years after the onset of SSc.…”

Section: Systemic Sclerosismentioning

confidence: 99%

Autoimmune Disorders and Lymphomas

Dolcetti¹,

Ponzoni²,

Mappa³

et al. 2011

Autoimmune Disorders - Pathogenetic Aspects

View full text Add to dashboard Cite

Malignancy in scleroderma patients from south west England: a population-based cohort study

Cited by 36 publications

References 17 publications

Complications in the treatment of oropharyngeal carcinoma in patients with systemic sclerosis: A case report

Complications in the treatment of oropharyngeal carcinoma in patients with systemic sclerosis: A case report

Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study

Autoimmune Disorders and Lymphomas

Contact Info

Product

Resources

About